Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Preliminary phase 1 data presented at the 2026 ESMO Congress show that INCB123667, a novel CDK2 inhibitor, combined with bevacizumab achieved a 48% response rate in heavily pretreated patients with platinum-resistant ovarian cancer. Notably, the combo worked even in patients who had already failed PARP inhibitors and prior bevacizumab therapy.
Patients with platinum-resistant ovarian cancer — one of the toughest-to-treat cancer populations — may have a new option on the horizon. Preliminary data from a phase 1 trial presented at the 2026 ESMO Congress show that INCB123667, a selective oral CDK2 inhibitor, combined with bevacizumab, delivered meaningful responses in heavily pretreated patients whose tumors overexpress cyclin E1, a protein linked to poor prognosis and reduced benefit from standard therapies.
The combination showed durable activity even in patients who had previously progressed on PARP inhibitors or bevacizumab itself — two groups historically with very limited options. A phase 3 trial (MAESTRA 3) evaluating the combo as first-line maintenance therapy is expected to launch in 2026.
By the Numbers:
Why it matters: Platinum-resistant ovarian cancer carries a grim prognosis with few effective treatments. This combination's strong response rates — even in patients who've exhausted multiple prior therapies — signal a potentially meaningful new treatment pathway for a population in urgent need.
